In a filing, Avidity Biosciences Inc revealed its Director WILSON TROY EDWARD unloaded Company’s shares for reported $1.48 million on Sep 05 ’25. In the deal valued at $50.00 per share,29,500 shares were sold. As a result of this transaction, WILSON TROY EDWARD now holds 54,425 shares worth roughly $2.54 million.
Then, Boyce Sarah sold 50,000 shares, generating $2,497,435 in total proceeds. Upon selling the shares at $49.95, the President and CEO now owns 305,871 shares.
Before that, Mosbrooker Eric sold 6,563 shares. Avidity Biosciences Inc shares valued at $308,936 were divested by the Chief Commercial Officer at a price of $47.07 per share. As a result of the transaction, Mosbrooker Eric now holds 55,000 shares, worth roughly $2.56 million.
A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”an Outperform”‘ rating. Wolfe Research began covering RNA with “an Outperform” recommendation on June 17, 2025. Raymond James started covering the stock on June 11, 2025. It rated RNA as “a Strong buy”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -2.98% to $46.62. Over the last five days, the stock has lost -1.29%. Avidity Biosciences Inc shares have risen nearly 14.38% since the year began. Nevertheless, the stocks have risen 60.32% over the past one year. While a 52-week high of $56.00 was reached on 09/05/25, a 52-week low of $21.51 was recorded on 04/09/25.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 45.67, which if violated will result in even more drops to 44.72. On the upside, there is a resistance level at 47.78. A further resistance level may holdings at 48.94.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-08-15, dropping by -0.59 million shares to a total of 15.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 16.26 million shares. There was a decline of -3.75%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
